Identification of HIV-1 Tat peptides for future therapeutic angiogenesis

European Journal of Haematology

Volumn 77, Issue 2, 2006, Pages 157-165

  Ismail, Mahmoud ^a   Henklein, Peter ^a   Huang, Xiaohua ^a   Braumann, Chris ^a   Rückert, Ralph I ^b   Dubiel, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Franziskus Hospital Berlin   (Germany)

Author keywords

Angiogenesis; Cell invasion; Human immunodeficiency virus type 1 Tat peptides; Peripheral vascular disease; Plasminogen activator inhibitor 1; Tubulogenesis

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CURCUMIN; MATRIGEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASOME; PROTEIN C JUN; TATPEP15; TATPEP16; TATPEP5; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMB ISCHEMIA; PEPTIDE SYNTHESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN SYNTHESIS; REVASCULARIZATION; THERAPEUTIC ANGIOGENESIS; TUBE; TUBULOGENESIS; UMBILICAL VEIN; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INDUCING AGENTS; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; GENE PRODUCTS, TAT; GENES, JUN; GENES, TAT; HIV-1; HUMANS; ISCHEMIA; LAMININ; MORPHOGENESIS; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-JUN; SP1 TRANSCRIPTION FACTOR; UMBILICAL VEINS;

EID: 33745727583     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00682.x     Document Type: Article

References (47)

1. POLLMANN C, HUANG X, MALL J, BECH-OTSCHIR D, NAUMANN M, DUBIEL W. The constitutive photomorphogenesis 9 signalosome directs vascular endothelial growth factor production in tumor cells. Cancer Res 2001;61:8416-8421.
2. ZHANG G, DASS CR, SUMITHRAN E, DI GIROLAMO N, SUN LQ, KHACHIGIAN LM. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004;96:683-696.
3. MCMAHON GA, PETITCLERC E, STEFANSSON S, SMITH E, WONG MK, WESTRICK RJ, GINSBURG D, BROOKS PC, LAWRENCE DA. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-33968.
4. VOGTEN JM, REIJERKERK A, MEIJERS JC, VOEST EE, BOREL RINKES IH, GEBBINK MF. The role of the fibrinolytic system in corneal angiogenesis. Angiogenesis 2003;6:311-316.
5. BAJOU K, MAILLARD C, JOST M, LIJNEN RH, GILS A, DECLERCK P, CARMELIET P, FOIDART JM, NOEL A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-6990.
6. CHEN YQ, SU M, WALIA RR, HAO Q, COVINGTON JW, VAUGHAN DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 1998;273:8225-8231.
7. ARTS J, GRIMBERGEN J, TOET K, KOOISTRA T. On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1alpha in HepG2 cells. Arterioscler Thromb Vasc Biol 1999;19:39-46.
8. PEPPER MS, FERRARA N, ORCI L, MONTESANO R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
9. LOSKUTOFF DJ, CURRIDEN SA, HU G, DENG G. Regulation of cell adhesion by PAI-1. APMIS 1999;107:54-61.
10. OSSOWSKI L, AGUIRRE-GHISO JA. Urokinase receptor and integrin partnership: co-ordination of signaling for cell adhesion, migration, and growth. Curr Opin Cell Biol 2000;12:613-620.
11. PREISSNER KT, KANSE SM, MAY AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000;12:621-628.
12. GASPARINI G, LONGO R, TOI M, FERRARA N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005;2:562-577.
13. OURIEL K. Peripheral arterial disease. Lancet 2001;358:1257-1264.
14. LUTHER M, LEPANTALO M, ALBACK A, MATZKE S. Amputation rates as a measure of vascular surgical results. Br J Surg 1996;83:241-244.
15. BAUMGARTNER I, SCHAINFELD R, GRAZIANI L. Management of peripheral vascular disease. Annu Rev Med 2005;56:249-272.
16. RUBARTELLI A, POGGI A, SITIA R, ZOCCHI MR. HIV-I Tat: a polypeptide for all seasons. Immunol Today 1998;19:543-545.
17. ALBINI A, BARILLARI G, BENELLI R, GALLO RC, ENSOLI B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995;92:4838-4842.
18. BARILLARI G, ENSOLI B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002;15:310-326.
19. MARCHIO S, ALFANO M, PRIMO L, et al. Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 2005;105:2802-2811.
20. ALBINI A, SOLDI R, GIUNCIUGLIO D, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-1375.
21. RUSNATI M, PRESTA M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002;5:141-151.
22. SEEGER M, FERRELL K, FRANK R, DUBIEL W. HIV-1 tat inhibits the 20S proteasome and its 11S regulator-mediated activation. J Biol Chem 1997;272:8145-8148.
23. KLOETZEL PM. Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 2004;5:661-669.
24. HUANG X, SEIFERT U, SALZMANN U, HENKLEIN P, PREISSNER R, HENKE W, SIJTS AJ, KLOETZEL PM, DUBIEL W. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing. J Mol Biol 2002;323:771-782.
25. SEEGER M, KRAFT R, FERRELL K, BECH-OTSCHIR D, DUMDEY R, SCHADE R, GORDON C, NAUMANN M, DUBIEL W. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 1998;12:469-478.
26. IMAMURA H, TAKAO S, AIKOU T. A modified invasion-3-(4,5-dimethylthiazole- 2-yl)-2,5-diphenyltetrazolium bromide assay for quantitating tumor cell invasion. Cancer Res 1994;54:3620-3624.
27. MORALES DE, MCGOWAN KA, GRANT DS, MAHESHWARI S, BHARTIYA D, CID MC, KLEINMAN HK, SCHNAPER HW. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995;91:755-763.
28. KOK TW, YUE PY, MAK NK, FAN TP, LIU L, WONG RN. The anti-angiogenic effect of sinomenine. Angiogenesis 2005;8:3-12.
29. BECH-OTSCHIR D, SEEGER M, DUBIEL W. The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis. J Cell Sci 2002;115:467-473.
30. LIONTAS A, YEGER H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 2004;24:987-998.
31. FULLBECK M, HUANG X, DUMDEY R, FROMMEL C, DUBIEL W, PREISSNER R. Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 2005;5:97.
32. ARBISER JL, KLAUBER N, ROHAN R, VAN LEEUWEN R, HUANG MT, FISHER C, FLYNN E, BYERS HR. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998;4:376-383.
33. BAUMGARTNER I, ISNER JM. Somatic gene therapy in the cardiovascular system. Annu Rev Physiol 2001;63:427-450.
34. BAUMGARTNER I, PIECZEK A, MANOR O, BLAIR R, KEARNEY M, WALSH K, ISNER JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-1123.
35. VALE PR, ISNER JM, ROSENFIELD K. Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 2001;14:511-528.
36. ISNER JM, VALE PR, SYMES JF, LOSORDO DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001;89:389-400.
37. CELLETTI FL, HILFIKER PR, GHAFOURI P, DAKE MD. Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 2001;37:2126-2130.
38. CELLETTI FL, WAUGH JM, AMABILE PG, BRENDOLAN A, HILFIKER PR, DAKE MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429.
39. BARILLARI G, SGADARI C, FIORELLI V, et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1999;94:663-672.
40. VIVES E, BRODIN P, LEBLEU B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017.
41. DIEM R, TAHERI N, DIETZ GP, KUHNERT A, MAIER K, SATTLER MB, GADJANSKI I, MERKLER D, BAHR M. HIV-Tat-mediated Bcl-XL delivery protects retinal ganglion cells during experimental autoimmune optic neuritis. Neurobiol Dis 2005;20:218-226.
42. KILIC E, KILIC U, HERMANN DM. TAT fusion proteins against ischemic stroke: current status and future perspectives. Front Biosci 2006;11:1716-1721.
43. FAWELL S, SEERY J, DAIKH Y, MOORE C, CHEN LL, PEPINSKY B, BARSOUM J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994;91:664-668.
44. DANIEL KG, KUHN DJ, KAZI A, DOU QP. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets 2005;5:529-541.
45. GLICKMAN MH, CIECHANOVER A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002;82:373-428.
46. BECH-OTSCHIR D, KRAFT R, HUANG X, HENKLEIN P, KAPELARI B, POLLMANN C, DUBIEL W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 2001;20:1630-1639.
47. BELLO L, GIUSSANI C, CARRABBA G, PLUDERI M, COSTA F, BIKFALVI A. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004;117:263-284.